Earnings Call · Q3 FY2022·2022-11-07

Q3 22EPS -42.86%·Rev n/aQ2 22EPS -16.67%·Rev n/aQ1 22EPS -13.64%·Rev n/aQ4 21EPS +78.26%·Rev n/a⚠ consensus missing

OCULAR THERAPEUTIX, INC OCUL

Donald Notman — CFO

Antony Mattessich — CEO

Rabia Ozden — Unknown

Peter Kaiser — Unknown

+1.4%1d on move date+0.5% vs SPY3d−20.3%5d−6.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more OCUL calls or request research access.

More OCUL calls Browse calls Request research access